WETZIKON - The fight over GZO Spital Wetzikon has a new number. Infracore said on Monday that it has promised nine institutional creditors a cash offer of CHF 70 million for all of the hospital's real estate and operating assets, to be filed if the composition agreement fails. The nine, Infracore said, hold claims of about CHF 130 million. That is more than half of the claims entitled to vote on the deal. They have rejected the agreement in writing and welcomed an Infracore bid.
The hospital would keep running
Infracore said it has prepared the takeover of day-to-day care with Swiss Medical Network, part of the Aevis group, so the hospital would not close in the handover. The offer is conditional. It goes in only once it is clear that the composition agreement has failed. Until then, the deal already in front of creditors is the one that counts.
That deal prefers Thurmed, the hospital group owned by the canton of Thurgau. It includes a binding convertible loan that would give Thurmed the right to buy 51 percent of GZO by the end of 2027. Infracore had looked out of the running once that text was the one put to creditors.
An earlier bid was turned down
GZO had already refused a revised Infracore proposal. After looking at the improved offer, the hospital said there was not enough time left to reach a result it could stand behind, and that creditors would not be given an alternative agreement. In September, Infracore's cash figure was CHF 55 million, with liquidity promised on top. Monday's commitment lifts the cash line to 70 million and ties it to the creditors who can block the Thurmed path.
The vote count runs to 4 December
Creditors met last Wednesday. There is still no official result. The administrators have to tally the written votes, and the composition court expects their report by 4 December at the latest. The court then decides whether the quorum was reached. Until that ruling, Wetzikon has two futures on paper: a Thurgau majority shareholder if the agreement passes, or a CHF 70 million cash sale to Infracore and Swiss Medical Network if it does not.
The hospital's fate sits inside a wider squeeze on care costs. Premiums are already set to rise by about 5 percent in 2027, and a separate study out on Monday warns that US pressure on medicine prices could add hundreds of millions more. For Wetzikon, the next hard date is the administrators' report in December.
